Glofitamab

Cytokine Release Syndrome

  • Cytokine Release Syndrome (CRS), including serious or fatal reactions, can occur in patients receiving COLUMVI.
  • Premedicate before each dose, and initiate treatment with the COLUMVI step-up dosing schedule to reduce the risk of CRS.
  • Withhold COLUMVI until CRS resolves or permanently discontinue based on severity

Medical guidelines

FDA Med Guides

Package inserts

Columvi

Keywords: Columvi
Updated: June 2023